Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

Influenza, Human Clinical Trial

Official title:

Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03658629
• Other study ID #: qNIV-E-201
• Status: Terminated
• Phase: Phase 2
• Start date: September 24, 2018
• Est. completion date: April 26, 2019

Study information

• Verified date: November 2022
• Source: Novavax
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase 2 trial to confirm the dose and formulation, demonstrate adjuvant effect, and evaluate the safety and tolerability of a single intramuscular injection of Quad-NIV with or without Matrix-M1 adjuvant in healthy adults ≥ 65 years of age. A total of approximately 1375 subjects were to be randomized to seven treatment groups to receive Quad-NIV or an active comparator.

Description:

This randomized, observer-blind, active-controlled, Phase 2 trial was conducted at multiple sites. The composition of the Quad-NIV Influenza Vaccines used in this trial included recombinant H1, H3, and two B hemagglutinin proteins for the 2018-2019 Northern Hemisphere influenza virus strains. Approximately 1375 healthy male and female subjects ≥ 65 years were randomized into 7 treatment groups (group A to group G), receiving various formulations of Quad-NIV, with or without Matrix-M1 adjuvant or one of two active comparator influenza vaccines. Within each site, randomization was stratified by history of receipt of 2017-2018 influenza vaccine. Subjects received two injections 28 days apart. On Day 0, subjects received one of the five Quad-NIV formulations or one of the two comparator influenza vaccines. On Day 28, subjects received either placebo or a licensed influenza vaccine rescue dose, depending on his or her initial randomization. Subjects were followed for safety for approximately 6 months, with primary immunogenicity results at Day 28.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1375
• Est. completion date: April 26, 2019
• Est. primary completion date: April 26, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

1. Clinically-stable adult male or female, = 65 years of age. Subjects may have 1 or more

chronic medical diagnoses, but should be clinically stable as assessed by:

• Absence of changes in medical therapy within 1 month due to treatment failure or toxicity,
• Absence of medical events qualifying as serious adverse events within 2 months; and
• Absence of known, current, and life-limiting diagnoses which render survival to completion of the protocol unlikely in the opinion of the investigator.

2. Willing and able to give informed consent prior to trial enrollment, and

3. Living in the community and able to attend trial visits, comply with trial requirements, and provide timely, reliable, and complete reports of adverse events.

Exclusion Criteria:

1. Participation in research involving investigational product (drug / biologic / device) within 45 days before planned date of first injection.

2. Participation in any previous Novavax's influenza vaccine clinical trial(s).

3. History of a serious reaction to prior influenza vaccination, known allergy to constituents of licensed comparator vaccines or polysorbate 80.

4. History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza vaccine.

5. Received any vaccine in the 4 weeks preceding the trial vaccination and any influenza vaccine within 6 months preceding the trial vaccination.

6. Any known or suspected immunosuppressive illness, congenital or acquired, based on medical history and/or physical examination.

7. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the trial vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose = 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.

8. Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the trial vaccine or during the trial.

9. Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature = 38.0°C, on the planned day of vaccine administration).

10. Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of trial results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).

11. Known disturbance of coagulation.

12. Suspicion or recent history (within 1 year of planned vaccination) of alcohol or other substance abuse.

Related Conditions & MeSH terms

• Influenza, Human

Intervention

Biological:
• NanoFlu (Quad-NIV)
2018-2019 Investigational Quadrivalent Seasonal Influenza Vaccine

Other:
• Matrix-M Adjuvant
Adjuvant
• Placebo
Placebo

Biological:
• Fluzone HD
2018-2019 Licensed Trivalent Seasonal Influenza Vaccine
• Flublok Quadrivalent
2018-2019 Licensed Quadrivalent Seasonal Influenza Vaccine
• Influenza Vaccine
2018-19 Licensed Seasonal Influenza Vaccine

Locations

Country	Name	City	State
United States	US078	Cary	North Carolina
United States	US050	Dakota Dunes	South Dakota
United States	US135	Hollywood	Florida
United States	US056	Moncks Corner	South Carolina
United States	US025	Norfolk	Nebraska
United States	US018	Omaha	Nebraska
United States	US108	Raleigh	North Carolina
United States	US138	Rockville	Maryland
United States	US137	Salisbury	North Carolina
United States	US045	Savannah	Georgia
United States	US132	Statesville	North Carolina
United States	US013	Stockbridge	Georgia
United States	US071	Wilmington	North Carolina
United States	US063	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Novavax

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects With Adverse Events (AEs)	Adverse Events over the 7 days post-injection; all adverse events (including adverse changes in clinical laboratory parameters) through 21 days post-injection; and Medically Attended Adverse Events (MAEs), Serious Adverse Events (SAEs), and Significant New Medical Conditions (SNMCs) through 6 months post-injection.	Day 0 - Day 182
Primary	Hemagglutination Inhibition (HAI) Titers Specific for Vaccine Homologous A and B Influenza Strains Expressed as Geometric Man Titer (GMT)	HAI antibody titers specific for the HA receptor binding domains of vaccine homologous A and B strain(s) at Days 0 and Day 28 post-vaccination expressed as geometric man titer (GMT).	Day 0 - Day 28
Primary	HAI Titers Specific for Antigenically-drifted Influenza Strains Expressed as GMT	HAI antibody titers specific for at least 2 antigenically-drifted influenza strains, at Days 0 and 28 post-vaccination expressed as geometric man titer (GMT).	Day 0 - Day 28
Secondary	HAI Titers Specific for Vaccine-homologous A and B Influenza Strains Expressed as GMT	HAI antibody titers specific for the HA receptor binding domains of vaccine-homologous A and B strain(s) expressed as GMT on Day 0,28,56 and 182.	Day 0 - Day 182
Secondary	HAI Titers Specific for Vaccine-homologous A and B Influenza Strains Expressed as Geometric Mean Fold Ratio (GMFR)	HAI antibody titers specific for the HA receptor binding domains of vaccine-homologous A and B strain(s) expressed as GMFR on Day 28,56 and 182.	Day 28 - Day 182
Secondary	Number of Participants Who Seroconverted as Determined by HAI Titers Specific for Vaccine-homologous A and B Influenza Strains	HAI antibody titers specific for the HA receptor binding domains of vaccine-homologous A and B strain(s) expressed as SCR on Day 28,56 and 182.	Day 28 - Day 182
Secondary	Number of Participants Who Had Seroprotection as Determined by HAI Titers Specific for Vaccine-homologous A and B Influenza Strains	HAI antibody titers specific for the HA receptor binding domains of vaccine-homologous A and B strain(s) expressed as SPR on Day 28,56 and 182.	Day 28 - Day 182
Secondary	HAI Titers Specific for Antigenically-drifted Influenza Strains Expressed as GMT	HAI antibody titers specific for antigenically-drifted influenza strains, at Days 0,28, 56 and 182 expressed as geometric man titer (GMT).	Day 0 - Day 182
Secondary	HAI Titer Responses Specific for Antigenically-drifted Influenza Strains Expressed as GMFR	HAI antibody titer responses specific for antigenically-drifted influenza strains, at Days 28, 56, and 182 expressed as Geometric Fold Ratio.	Day 28 - Day 182
Secondary	Number of Participants Who Seroconverted as Determined by HAI Titers Specific for Antigenically-drifted Influenza Strains	HAI antibody titers specific for antigenically-drifted influenza strains, at Days 28, 56 and 182 expressed as SCR.	Day 28 - Day 182
Secondary	Number of Participants Who Had Seroprotection as Determined by HAI Titers of Antigenically-drifted Influenza Strains	HAI antibody titers specific for antigenically-drifted influenza strains, at Days 28, 56 and 182 expressed as SPR.	Day 28 - Day 182

External Links

•   Related Info